

Andreas Lundqvist

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7041531/publications.pdf>

Version: 2024-02-01

140
papers

6,061
citations

87888

38
h-index

76900

74
g-index

142
all docs

142
docs citations

142
times ranked

9315
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer classification using the Immunoscore: a worldwide task force. <i>Journal of Translational Medicine</i> , 2012, 10, 205.	4.4	676
2	Heat-shock proteins as activators of the innate immune system. <i>Trends in Immunology</i> , 2002, 23, 130-135.	6.8	534
3	Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. <i>Cytotherapy</i> , 2009, 11, 341-355.	0.7	257
4	Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity. <i>Clinical Cancer Research</i> , 2014, 20, 4096-4106.	7.0	230
5	A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. <i>British Journal of Cancer</i> , 2004, 91, 688-694.	6.4	172
6	Melanoma-Educated CD14+ Cells Acquire a Myeloid-Derived Suppressor Cell Phenotype through COX-2-Dependent Mechanisms. <i>Cancer Research</i> , 2013, 73, 3877-3887.	0.9	160
7	The Role of CXC Chemokine Receptors CXCR4 on Immune Cells in the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2018, 9, 2159.	4.8	158
8	Bortezomib and Depsipeptide Sensitize Tumors to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand: A Novel Method to Potentiate Natural Killer Cell Tumor Cytotoxicity. <i>Cancer Research</i> , 2006, 66, 7317-7325.	0.9	146
9	CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment. <i>Journal of Clinical Investigation</i> , 2020, 130, 1185-1198.	8.2	139
10	CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 225-235.	4.2	136
11	IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells. <i>Blood</i> , 2016, 128, 1475-1489.	1.4	136
12	Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. <i>Journal of Clinical Investigation</i> , 2008, 118, 1584-1584.	8.2	135
13	Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. <i>Journal of Clinical Investigation</i> , 2008, 118, 1099-109.	8.2	118
14	Tissue distribution and differential expression of melanocortin 1 receptor, a malignant melanoma marker. <i>British Journal of Cancer</i> , 2002, 87, 414-422.	6.4	106
15	Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma. <i>Journal of Clinical Investigation</i> , 2017, 127, 73.		106
16	Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma. <i>Oncotarget</i> , 2017, 8, 21539-21553.	1.8	103
17	Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2005, 128, 668-675.	2.5	102
18	Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2006, 133, 305-314.	2.5	102

#	ARTICLE	IF	CITATIONS
19	Immobilized Membrane Vesicle or Proteoliposome Affinity Chromatography. Frontal Analysis of Interactions of Cytochalasin B and D-Glucose with the Human Red Cell Glucose Transporter. <i>Biochemistry</i> , 1996, 35, 12141-12145.	2.5	94
20	Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. <i>Blood</i> , 2009, 113, 6120-6127.	1.4	90
21	Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors. <i>Blood</i> , 2007, 109, 3603-3606.	1.4	88
22	Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer Immunotherapy. <i>Cancers</i> , 2020, 12, 3586.	3.7	75
23	Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis. <i>Experimental Hematology</i> , 2006, 34, 796-801.	0.4	74
24	Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2005, 131, 74-79.	2.5	73
25	Fetal and adult multipotent mesenchymal stromal cells are killed by different pathways. <i>Cytotherapy</i> , 2011, 13, 269-278.	0.7	67
26	Natural killer cell immunotherapy for cancer: a new hope. <i>Cytotherapy</i> , 2008, 10, 775-783.	0.7	66
27	Bortezomib Treatment to Potentiate the Anti-tumor Immunity of Ex-vivo Expanded Adoptively Infused Autologous Natural Killer Cells. <i>Journal of Cancer</i> , 2011, 2, 383-385.	2.5	66
28	Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. <i>Blood</i> , 2009, 113, 875-882.	1.4	61
29	Mature dendritic cells are protected from Fas/CD95-mediated apoptosis by upregulation of Bcl-X L. <i>Cancer Immunology, Immunotherapy</i> , 2002, 51, 139-144.	4.2	55
30	HLA-dependent tumour development: a role for tumour associate macrophages?. <i>Journal of Translational Medicine</i> , 2013, 11, 247.	4.4	55
31	Doxorubicin sensitizes human tumor cells to NK cell-mediated killing by augmented TRAIL receptor signaling. <i>International Journal of Cancer</i> , 2013, 133, 1643-1652.	5.1	54
32	Exhaustion of CD4+ T-cells mediated by the Kynurenine Pathway in Melanoma. <i>Scientific Reports</i> , 2019, 9, 12150.	3.3	54
33	Thioredoxin activity confers resistance against oxidative stress in tumor-infiltrating NK cells. <i>Journal of Clinical Investigation</i> , 2020, 130, 5508-5522.	8.2	52
34	HER2/HER3 Signaling Regulates NK Cell-Mediated Cytotoxicity via MHC Class I Chain-Related Molecule A and B Expression in Human Breast Cancer Cell Lines. <i>Journal of Immunology</i> , 2012, 188, 2136-2145.	0.8	51
35	Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis. <i>Oncolmmunology</i> , 2016, 5, e1052213.	4.6	51
36	Acoustic formation of multicellular tumor spheroids enabling on-chip functional and structural imaging. <i>Lab on A Chip</i> , 2018, 18, 2466-2476.	6.0	51

#	ARTICLE	IF	CITATIONS
37	Human Anaplastic Thyroid Carcinoma Cells Are Sensitive to NK Cell-Mediated Lysis via ULBP2/5/6 and Chemoattract NK Cells. <i>Clinical Cancer Research</i> , 2014, 20, 5733-5744.	7.0	47
38	Gap Junction Intercellular Communications Regulate NK Cell Activation and Modulate NK Cytotoxic Capacity. <i>Journal of Immunology</i> , 2014, 192, 1313-1319.	0.8	42
39	Nonviral and Viral Gene Transfer Into Different Subsets of Human Dendritic Cells Yield Comparable Efficiency of Transfection. <i>Journal of Immunotherapy</i> , 2002, 25, 445-454.	2.4	40
40	Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors. <i>Cancers</i> , 2019, 11, 1040.	3.7	40
41	Allogeneic Hematopoietic Cell Transplantation as Immunotherapy for Solid Tumors. <i>Journal of Immunotherapy</i> , 2005, 28, 281-288.	2.4	38
42	Targeting the tumor microenvironment to improve natural killer cell-based immunotherapies: On being in the right place at the right time, with resilience. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 607-611.	3.3	38
43	AMD3100 Mobilized Apheresis Products Are Rich in T-Cells That Do Not Undergo a Th-2 Type Cytokine Polarization: Implications for Allografting. <i>Blood</i> , 2005, 106, 296-296.	1.4	38
44	Optimizing Lentiviral Transduction of Human Natural Killer Cells. <i>Blood</i> , 2011, 118, 4714-4714.	1.4	37
45	Immobilized-biomembrane affinity chromatography for binding studies of membrane proteins. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 768, 31-40.	2.3	35
46	Dendritic cell regulation of NK cell responses involves lymphotoxin-1, IL-12, and TGF- β 2. <i>European Journal of Immunology</i> , 2015, 45, 1783-1793.	2.9	34
47	Chromatography on cells and biomolecular assemblies. <i>Biomedical Applications</i> , 1997, 699, 209-220.	1.7	32
48	Visualization of human T lymphocyte-mediated eradication of cancer cells in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 22910-22919.	7.1	32
49	Immobilization of human red cells in gel particles for chromatographic activity studies of the glucose transporter Glut1. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1997, 1325, 91-98.	2.6	31
50	Differences in the Phenotype, Cytokine Gene Expression Profiles, and In Vivo Alloreactivity of T Cells Mobilized with Plerixafor Compared with G-CSF. <i>Journal of Immunology</i> , 2013, 191, 6241-6249.	0.8	31
51	Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon- β and multiple toll-like receptor agonists. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1333-1344.	4.2	31
52	Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination. <i>Oncolmmunology</i> , 2020, 9, 1792058.	4.6	30
53	Cutting Edge: Bortezomib-Treated Tumors Sensitized to NK Cell Apoptosis Paradoxically Acquire Resistance to Antigen-Specific T Cells. <i>Journal of Immunology</i> , 2010, 184, 1139-1142.	0.8	29
54	PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates. <i>Oncolmmunology</i> , 2020, 9, 1786888.	4.6	29

#	ARTICLE	IF	CITATIONS
55	The Multifaceted Roles of CXCL9 Within the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1231, 45-51.	1.6	29
56	Correlation between HLA-A2 Gene Frequency, Latitude, Ovarian and Prostate Cancer Mortality Rates. <i>Medical Oncology</i> , 2004, 21, 49-52.	2.5	28
57	Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2010, 116, 2858-2859.	1.4	28
58	A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1359-1368.	4.2	27
59	Recombinant Adenovirus Vector Activates and Protects Human Monocyte-Derived Dendritic Cells from Apoptosis. <i>Human Gene Therapy</i> , 2002, 13, 1541-1549.	2.7	26
60	Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0139809.	2.5	26
61	Cripto-1 Plasmid DNA Vaccination Targets Metastasis and Cancer Stem Cells in Murine Mammary Carcinoma. <i>Cancer Immunology Research</i> , 2018, 6, 1417-1425.	3.4	25
62	Activated monocytes augment TRAIL-mediated cytotoxicity by human NK cells through release of IFN γ . <i>European Journal of Immunology</i> , 2013, 43, 249-257.	2.9	23
63	d-Glucose, forskolin and cytochalasin B affinities for the glucose transporter Glut1. <i>Journal of Chromatography A</i> , 1997, 776, 81-86.	3.7	21
64	Major Histocompatibility Complex-I Expression on Embryonic Stem Cell-Derived Vascular Progenitor Cells Is Critical for Syngeneic Transplant Survival. <i>Stem Cells</i> , 2010, 28, 1465-1475.	3.2	21
65	Cripto-1 vaccination elicits protective immunity against metastatic melanoma. <i>Oncolmmunology</i> , 2016, 5, e1128613.	4.6	21
66	Development of a technology platform for large-scale clinical grade production of DC. <i>Cytotherapy</i> , 2004, 6, 363-371.	0.7	20
67	Mature Dendritic Cells Induce Tumor-Specific Type 1 Regulatory T Cells. <i>Journal of Immunotherapy</i> , 2005, 28, 229-235.	2.4	20
68	Interleukin β 3 is a Novel Immunosuppressor that Protects Cancer Cells from TIL Killing by a Macrophage-Mediated Shedding Mechanism. <i>Advanced Science</i> , 2021, 8, 2101029.	11.2	20
69	Glucose affinity for the glucose transporter Glut1 in native or reconstituted lipid bilayers. <i>Journal of Chromatography A</i> , 1997, 776, 87-91.	3.7	19
70	Conversion between two cytochalasin B-binding states of the human GLUT1 glucose transporter. <i>FEBS Journal</i> , 2000, 267, 6875-6882.	0.2	19
71	Zoledronic acid inhibits NFAT and IL-2 signaling pathways in regulatory T cells and diminishes their suppressive function in patients with metastatic cancer. <i>Oncolmmunology</i> , 2017, 6, e1338238.	4.6	19
72	Freeze-thaw immobilization of liposomes in chromatographic gel beads: evaluation by confocal microscopy and effects of freezing rate. , 1998, 11, 52-57.		18

#	ARTICLE	IF	CITATIONS
73	Allogeneic Tumor-Dendritic Cell Fusion Vaccines for Generation of Broad Prostate Cancer T-Cell Responses. <i>Medical Oncology</i> , 2004, 21, 155-166.	2.5	18
74	Regulation of TRAIL-Receptor Expression by the Ubiquitin-Proteasome System. <i>International Journal of Molecular Sciences</i> , 2014, 15, 18557-18573.	4.1	18
75	Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress. , 2022, 10, e004458.		18
76	Genetically modified immune cells targeting tumor antigens. , 2020, 214, 107603.		17
77	Advantages of quantitative affinity chromatography for the analysis of solute interaction with membrane proteins. <i>Journal of Proteomics</i> , 2001, 49, 507-521.	2.4	16
78	Effects of human plasma proteins on maturation of monocyte-derived dendritic cells. <i>Immunology Letters</i> , 2005, 100, 113-119.	2.5	16
79	Biomembrane affinity chromatographic analysis of inhibitor binding to the human red cell nucleoside transporter in immobilized cells, vesicles and proteoliposomes. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1998, 1371, 1-4.	2.6	15
80	Frontal affinity chromatographic analysis of membrane protein reconstitution. <i>Materials Science and Engineering C</i> , 1997, 4, 221-226.	7.3	14
81	Engineered NK Cells Against Cancer and Their Potential Applications Beyond. <i>Frontiers in Immunology</i> , 2022, 13, 825979.	4.8	14
82	Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib. <i>Lancet Oncology</i> , The, 2005, 6, 809-812.	10.7	13
83	Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3155-3166.	4.2	13
84	Gene-Modified Dendritic Cells for Immunotherapy Against Cancer. <i>Medical Oncology</i> , 2002, 19, 197-212.	2.5	11
85	Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours. <i>Journal of Translational Medicine</i> , 2012, 10, 104.	4.4	11
86	Biomembrane affinity chromatographic analysis of nitrobenzylthioinosine binding to the reconstituted human red cell nucleoside transporter. , 1998, 11, 58-61.		10
87	Adoptively-Infused NK Cells Maintain Their Antitumor Effects in Vivo in the Presence of CyclosporineA (CSA). <i>Blood</i> , 2008, 112, 2563-2563.	1.4	10
88	Overexpression and functional characterisation of the human melanocortin 4 receptor in Sf9 cells. <i>Protein Expression and Purification</i> , 2004, 37, 455-461.	1.3	9
89	Phosphodiesterase 4A confers resistance to PGE2-mediated suppression in CD25 ⁺ /CD54 ⁺ NK cells. <i>EMBO Reports</i> , 2021, 22, e51329.	4.5	8
90	A _{2B} adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models. , 2022, 10, e004592.		8

#	ARTICLE	IF	CITATIONS
91	Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients. <i>Immunobiology</i> , 2014, 219, 189-197.	1.9	7
92	B7-H7 Is Inducible on T Cells to Regulate Their Immune Response and Serves as a Marker for Exhaustion. <i>Frontiers in Immunology</i> , 2021, 12, 682627.	4.8	7
93	Regulatory T Cells Inhibit T Cell Activity by Downregulating CD137 Ligand via CD137 Trogocytosis. <i>Cells</i> , 2021, 10, 353.	4.1	6
94	Biomembrane-affinity centrifugal analyses of solute interactions with membrane proteins. <i>Journal of Chromatography A</i> , 1999, 852, 93-96.	3.7	5
95	Impact of KIR and HLA Genotypes on Outcome in Nonmyeloablative Hematopoietic Cell Transplantation (HCT) Using HLA Matched Related Donors.. <i>Blood</i> , 2006, 108, 323-323.	1.4	5
96	Sarcoma Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1296, 319-348.	1.6	5
97	Bortezomib Treatment Of Primitive Quiescent CD34+ Cell S In Chronic Myeloid Leukemia Enhances Targeting By In Vitro Expanded Allogeneic Natural Killer Cell S. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 126-127.	2.0	4
98	In Vitro-Expanded NK Cells Have Increased TRAIL and NKG2D Expression and Enhanced TRAIL-Mediated Tumor Cytotoxicity Compared to Non-Expanded NK Cells.. <i>Blood</i> , 2007, 110, 2744-2744.	1.4	4
99	In Vitro Expanded NK Cells Have Increased Natural Cytotoxicity Receptors, TRAIL and NKG2D Expression, and Superior Tumor Cytotoxicity Compared to Short-Term IL-2 "Activated NK Cells.. <i>Blood</i> , 2009, 114, 463-463.	1.4	4
100	Significant Alterations in T-Cell TH1 and TH2 Cytokine Gene Profiles Associated with G-CSF Mobilization Do Not Occur in T-Cells Mobilized with AMD3100.. <i>Blood</i> , 2007, 110, 3277-3277.	1.4	3
101	A Phase I Trial of Adoptively Transferred Ex-Vivo Expanded Autologous Natural Killer (NK) Cells Following Treatment with Bortezomib to Sensitize Tumors to NK Cell Cytotoxicity. <i>Blood</i> , 2011, 118, 1001-1001.	1.4	3
102	Opposing consequences of signaling through EGF family members. <i>Oncolmmunology</i> , 2012, 1, 1200-1201.	4.6	2
103	âœœMarkers and function of human NK cells in normal and pathological conditions.âœœ <i>Cytometry Part B - Clinical Cytometry</i> , 2017, 92, 98-99.	1.5	2
104	CD11c-CD8 Spatial Cross Presentation: A Novel Approach to Link Immune Surveillance and Patient Survival in Soft Tissue Sarcoma. <i>Cancers</i> , 2021, 13, 1175.	3.7	2
105	Abstract 1271: <i>In vitro</i> expanded natural killer (NK) cells are more susceptible to Fas-mediated apoptosis compared to fresh and overnight IL-2 activated NK cells. <i>Cancer Research</i> , 2010, 70, 1271-1271.	0.9	2
106	A Detailed Phenotypic Analysis Using Six Color Flow Cytometry of Lymphocyte Subsets Mobilized with AMD3100 Compared to G-CSF.. <i>Blood</i> , 2004, 104, 408-408.	1.4	2
107	Bortezomib Enhances the Antitumor Activity of Adoptively Infused Natural Killer Cells In Vivo: A Novel Approach To Override KIR-Mediated Inhibition of NK Cell Cytotoxicity.. <i>Blood</i> , 2007, 110, 1786-1786.	1.4	2
108	Cyclosporine A (CSA) Significantly Reduces the Cytotoxic Effects of In Vitro Expanded NK Cells: Implications for Adoptive NK Cell Therapy in the Setting of Allogeneic Hematopoietic Stem Cell Transplantation (HCT).. <i>Blood</i> , 2007, 110, 4899-4899.	1.4	2

#	ARTICLE	IF	CITATIONS
109	Adoptive Infusion of Ex Vivo Expanded Autologous Natural Killer (NK) Cells in Cancer Patients Treated with Bortezomib to Sensitize to NK-TRAIL Cytotoxicity.. Blood, 2009, 114, 4080-4080.	1.4	2
110	Abstract A63: Melanoma-educated CD14+ monocytes become myeloid-derived suppressor cell-like and are potent inhibitors of autologous T cells through Cox-2 production and STAT-3 signaling.. , 2013, , .		2
111	Effects of pH, salt and time on ligand binding properties of overexpressed melanocortin 4 receptor. Journal of Proteomics, 2004, 58, 195-205.	2.4	1
112	Unlicensed natural born killers. Blood, 2011, 117, 6974-6975.	1.4	1
113	Evaluation of Breast Cancer and Melanoma Metastasis in Syngeneic Mouse Models. Methods in Molecular Biology, 2019, 1913, 197-206.	0.9	1
114	Editorial: NK-Myeloid Cell Interactions in the Tumor Microenvironment: Implications for Cancer Immunotherapy. Frontiers in Immunology, 2021, 12, 718844.	4.8	1
115	Adoptive Infusion of Allogeneic KIR Ligand Mismatched NK Cells Reduce GVHD in an MHC Matched Allogeneic Stem Cell Transplantation Model.. Blood, 2005, 106, 1310-1310.	1.4	1
116	In Vitro and In Vivo Sensitization of Malignant Cells to Autologous Natural Killer Cell Cytotoxicity Following Exposure to Bortezomib.. Blood, 2006, 108, 925-925.	1.4	1
117	Adoptive Transfer of Natural Killer (NK) Cells to Prevent Gvhd and Enhance GVT Effects After Allogeneic Hematopoietic Cell Transplantation (HCT): The Timing of Donor NK Cell Infusions Critically Impacts Transplant Outcome.. Blood, 2009, 114, 786-786.	1.4	1
118	Allograft Cell Content and GVHD Differ in Murine Recipients of AMD3100 Versus G-CSF Mobilized Peripheral Blood Stem Cells.. Blood, 2005, 106, 3108-3108.	1.4	1
119	Interleukinâ€³3 is a Novel Immunosuppressor that Protects Cancer Cells from TIL Killing by a Macrophageâ€¢Mediated Shedding Mechanism (Adv. Sci. 21/2021). Advanced Science, 2021, 8, .	11.2	1
120	Nephrotic syndrome associated with thrombotic microangiopathy following allogeneic stem cell transplantation for myelodysplastic syndrome ? response to Nakamura et al. British Journal of Haematology, 2007, 136, 859-860.	2.5	0
121	Solid tumors in adults. , 2009, , 137-145.		0
122	Natural Killer (NK) Cells Are Resistant to the Apoptotic Effects of Corticosteroids Compared to T Cells: Implications for Adoptive NK Cell Therapy Following Allogeneic HCT. Biology of Blood and Marrow Transplantation, 2009, 15, 9-10.	2.0	0
123	Potent Graft-Versus-Renal Cell Carcinoma (RCC) Effects in a Murine Minor Histocompatibility Antigen (mHa)-Mismatched Allogeneic Transplant Model.. Blood, 2004, 104, 4982-4982.	1.4	0
124	Complex Alterations in Serum Cytokines and Increased Il-4 Levels Characterize Patients Developing Chronic Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation.. Blood, 2004, 104, 4985-4985.	1.4	0
125	The Graft-vs-Host Hematopoietic Effect Generated after Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) Cures Patients with Severe PNH.. Blood, 2004, 104, 811-811.	1.4	0
126	Cd8+ T-Cells Specifically Cytotoxic to Renal Cell Carcinoma (RCC) Cells Can Be Isolated from Patients with Regressing Metastatic Kidney Cancer after Allogeneic Nonmyeloablative Hematopoietic Cell Transplantation (NMHCT).. Blood, 2004, 104, 4984-4984.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Adoptive Infusion of Alloreactive Donor NK Cells Reduces GVHD, Mediates Anti-Tumor Effects and Prolongs Survival in Recipients of MHC-Matched Hematopoietic Cell Transplantation.. Blood, 2006, 108, 3233-3233.	1.4	0
128	Pre-Transplant T-Cell Lymphopenia Accelerates Early Donor T-Cell and Myeloid Chimerism but Is Not Required for Full Donor Lymphohematopoietic Engraftment or To Prevent Graft Rejection Following Nonmyeloablative Hematopoietic Cell Transplantation (NST).. Blood, 2006, 108, 2981-2981.	1.4	0
129	Primitive Quiescent CD34+ Cells in Chronic Myeloid Leukemia Are Targeted by In Vitro Expanded Allogeneic Natural Killer Cells, Which Are Functionally Enhanced by Bortezomib Treatment.. Blood, 2007, 110, 1008-1008.	1.4	0
130	The Proteasome Inhibitor Bortezomib Simultaneously Enhances NK Cell Tumor Cytotoxicity While Paradoxically Reducing Antigen Specific T-Cell Tumor Cytotoxicity.. Blood, 2007, 110, 1789-1789.	1.4	0
131	A Rhesus Macaque Model to Optimize Adoptive NK Cell Therapy. Blood, 2008, 112, 3905-3905.	1.4	0
132	Lentiviral Transduction of Ex Vivo Expanded Natural Killer Cells with a CD19 Chimeric Antigen Receptor Induces Cytotoxicity against Resistant B Cell Malignancies. Blood, 2008, 112, 3540-3540.	1.4	0
133	A Highly Efficient Method to Expand CD3-CD56+ NK Cells from Cord Blood Segments. Blood, 2008, 112, 3902-3902.	1.4	0
134	Abstract A15: IFN-gamma-inducible-protein-10 stimulates intratumoral infiltration of adoptively transferred human NK cells in a melanoma xenograft mouse model.. , 2013, , .		0
135	Regulation of Natural Killer Cell Responses By Dendritic Cells Via Lymphotoxin-Alpha, Interleukin-12, and Tumor Growth Factor-Beta. Blood, 2014, 124, 4140-4140.	1.4	0
136	T Cell Blockade Immunotherapy Against Cancer and Abscopal Effect in Combination Therapy. Cancer Drug Discovery and Development, 2015, , 211-229.	0.4	0
137	Abstract B071: Enhanced IL-12 production and T cell stimulation ability by dendritic cells matured in presence of GMP-grade Toll-like receptor ligands and IFN- γ . , 2016, , .		0
138	Abstract A77: Cripto-1 vaccination elicits protective immune response to metastatic breast cancer and breast cancer stem cells. , 2018, , .		0
139	Strategies and Techniques for NK Cell Phenotyping. Methods in Molecular Biology, 2019, 2032, 105-114.	0.9	0
140	Ex Vivo Activity of Immunotherapeutic Approaches Targeting CD38 Against Daratumumab-Resistant Multiple Myeloma Patient Samples. Blood, 2019, 134, 1848-1848.	1.4	0